- Home
- XERS vs TCBX Comparison
XERS vs TCBX Comparison
Compare XERS & TCBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- TCBX
- Stock Information
- Founded
- XERS 2005
- TCBX 2008
- Country
- XERS United States
- TCBX United States
- Employees
- XERS N/A
- TCBX N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- TCBX Banks
- Sector
- XERS Health Care
- TCBX Finance
- Exchange
- XERS Nasdaq
- TCBX Nasdaq
- Market Cap
- XERS 500.2M
- TCBX 473.0M
- IPO Year
- XERS 2018
- TCBX 2021
- Fundamental
- Price
- XERS $3.47
- TCBX $34.36
- Analyst Decision
- XERS Buy
- TCBX Buy
- Analyst Count
- XERS 3
- TCBX 4
- Target Price
- XERS $4.87
- TCBX $25.50
- AVG Volume (30 Days)
- XERS 1.8M
- TCBX 77.6K
- Earning Date
- XERS 11-08-2024
- TCBX 01-23-2025
- Dividend Yield
- XERS N/A
- TCBX N/A
- EPS Growth
- XERS N/A
- TCBX 38.69
- EPS
- XERS N/A
- TCBX 2.56
- Revenue
- XERS $187,361,000.00
- TCBX $158,911,000.00
- Revenue This Year
- XERS $24.27
- TCBX N/A
- Revenue Next Year
- XERS $18.57
- TCBX $8.54
- P/E Ratio
- XERS N/A
- TCBX $13.40
- Revenue Growth
- XERS 22.72
- TCBX 17.73
- 52 Week Low
- XERS $1.69
- TCBX $18.00
- 52 Week High
- XERS $3.87
- TCBX $37.65
- Technical
- Relative Strength Index (RSI)
- XERS 54.75
- TCBX 47.10
- Support Level
- XERS $3.32
- TCBX $33.03
- Resistance Level
- XERS $3.57
- TCBX $37.37
- Average True Range (ATR)
- XERS 0.18
- TCBX 1.31
- MACD
- XERS -0.01
- TCBX -0.41
- Stochastic Oscillator
- XERS 42.86
- TCBX 28.79
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company has one segment, community banking, it generates most of its revenue from interest on loans, customer service, and loan fees.